ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 100

Further Evidence On Biased Cancer Risk Estimation in Studies Comparing A Subpopulation to the General Population

Koray Tascilar1 and Hasan Yazici2, 1University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose: We had previously proposed a selection bias in studies estimating cancer risk in patients with rheumatoid arthritis (RA) stemming from the comparison of a selected subpopulation to the general population (Arthritis Rheum. 2011;63;2543-4). Biased estimates would be the result of a) death of a part of the subpopulation due to cancer before being selected, b) prevention of an autoimmune/inflammatory condition by cancer treatment and c) a lower probability of being selected/detected merely because of having cancer. These would cause the rate of accumulation of cancer cases in the selected subpopulation to be lower than that in the general population  and hence a decrease in the comparative incidence if tracked over time. We had also demonstrated such a decrease in the comparative incidence over time in studies reporting cancer risk in RA patients (Ann Rheum Dis 2012;71(Suppl3):456). We conducted a systematic literature search to see whether such a bias exists in studies reporting the cancer risk in other autoimmune/inflammatory disorders.

Methods: We conducted multiple PubMed searches using the search terms “polymyositis”, “dermatomyositis”, “sarcoidosis”, “psoriasis”, “Crohn’s”, “ulcerative”, “lupus”, “SLE”, “Sjogren”, “ANCA”, “polyarteritis”, “Wegener”, “polyangiitis”, “vasculitis”, and “scleroderma” between June 2001 and February 2012. We combined these terms with “cancer” and “standardized” to capture studies that reported standardized incidence ratios or standardized morbidity ratios. We retrieved full-text manuscripts of studies that reported comparative incidence. Studies that reported multiple incidence ratios with respect to follow-up time were included.

Results: Our search identified 192 articles and we retrieved 36 articles of relevance in full-text. Among the 36 articles retrieved, 10 reported incidence comparison of overall cancer at multiple timepoints. There were 3 studies on inflammatory myopathies, 1 study each with scleroderma, Wegener’s granulomatosis, ulcerative colitis, Crohn’s disease, polymyalgia rheumatica, SLE and sarcoidosis. Number of timepoints ranged from 2 to 10, sampling period ranged from 10 to 48 years. The comparative incidence at the latest timepoint was lower in 9 of the 10 articles by 56 to 98% as compared to the earliest.

Conclusion: We provide further evidence that current methods of comparision of cancer incidence in a selected subpopulation to the general population results in biased estimates.


Disclosure:

K. Tascilar,
None;

H. Yazici,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/further-evidence-on-biased-cancer-risk-estimation-in-studies-comparing-a-subpopulation-to-the-general-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology